Public Profile

Shire US, Inc.

Shire US, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1986, the company has achieved significant milestones, including its focus on developing innovative therapies for rare diseases and specialty conditions. Shire is renowned for its core products, particularly in the fields of ophthalmology and rare genetic disorders, with Xiidra being a notable treatment for dry eye disease. The company’s commitment to patient-centric solutions and cutting-edge research distinguishes it in a competitive market. With a strong market position, Shire has garnered recognition for its contributions to improving patient outcomes and advancing healthcare solutions globally.

DitchCarbon Score

How does Shire US, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

54

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Shire US, Inc.'s score of 54 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Shire US, Inc.'s reported carbon emissions

Shire US, Inc. currently does not have available carbon emissions data or specific reduction targets outlined in their climate commitments. Without concrete figures or defined initiatives, it is challenging to assess their current impact on carbon emissions or their strategic approach to climate change. However, the absence of data may indicate a need for enhanced transparency and commitment to sustainability practices within the industry. As the global focus on climate action intensifies, it is essential for companies like Shire US, Inc. to establish clear emissions reduction goals and report on their progress to align with industry standards and stakeholder expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Shire US, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Shire US, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Shire US, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Novo Nordisk Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

CSL Behring LLC

US
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Aptalis Holdings Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Bioverativ Therapeutics Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Pfizer

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers